Quest Diagnostics Incorporated with ticker code (DGX) now have 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘Hold’. The range between the high target price and low target price is between 166 and 140 and has a mean target at $150.47. Given that the stocks previous close was at $142.34 and the analysts are correct then we can expect a percentage increase in value of 5.7%. The day 50 moving average is $140.46 and the 200 day moving average is $139.56. The total market capitalization for the company now stands at $16,009m. Visit the company website at: https://www.questdiagnostics.com
The potential market cap would be $16,923m based on the market consensus.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
The company has a dividend yield of 1.98% with the ex dividend date set at 6-4-2023 (DMY).
Other points of data to note are a P/E ratio of 17.95, revenue per share of 85.2 and a 7.34% return on assets.
